Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. MU
4. DPZ
5. ACN
6. NAVN
7. DFTX
8. IBM
9. META
10. ENRD

Go back to Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance

Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by Wide Margin; Guides FY23

March 1, 2023 4:16 PM EST

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of ($0.07), $4.58 worse than the analyst estimate of $4.51. Revenue for the quarter came in at $972.13 million versus the consensus estimate of $975.18 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2023 EPS of $16.90-$17.86, versus the consensus of $18.00. Jazz... More